Companies / Germany
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Teva, Mylan Compete For Merck KGaA's Generics Arm
May 2007 | Industry NewsSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
The race for the generics business of Germany's Merck KGaA looks to be heading into the final stages with two firms thought to be leading the bidding - Israel's Teva , and US-based Mylan. At the time of press, Teva appears to have the upper hand, due to its larger market cap, although company officials have been silent on the possibility of a deal. However, Mylan could still surprise with an aggressive offer.